FORA Capital’s Roivant Sciences ROIV Stock Holding History

FORA Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Sell	44,129 -9,280	-17%	-$274K	0.11%	181
2026 Q1	$1.48M	Sell	53,409 -10,453	-16%	-$269K	0.11%	190
2025 Q4	$1.39M	Buy	+63,862	New	+$1.26M	0.17%	152

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

FORA Capital's ROIV Position: Q2 2026 in Review

FORA Capital reduced its Roivant Sciences (ROIV) stake by 17% in Q2 2026, selling an estimated $274K and leaving 44,129 shares worth $1.56M. The position accounts for 0.11% of the portfolio, ranked #181.

FORA Capital first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

FORA Capital held 44,129 shares of Roivant Sciences worth $1.56M as of Q2 2026.
FORA Capital sold 9,280 Roivant Sciences shares in Q2 2026, an estimated $274K.
Roivant Sciences made up 0.11% of FORA Capital's portfolio in Q2 2026, its #181 holding.
FORA Capital first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.